Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: RXGOLF who wrote (29681)	12/16/1999 12:31:00 AM
From: Henry Niman	Read Replies (1) \| Respond to of 32384

I don't think that there was anything new in the JNCI article. Just used the rat data and presented in clinical terms. However, JNCI is read by clinicians and article could cause more off label use in a couple of months, especially in advanced breast cancer patients who have failed Tamoxifen treatment.

To: RXGOLF who wrote (29681)	12/16/1999 7:03:00 AM
From: Henry Niman	Respond to of 32384

Dow Jones on JNCI Report: Ligand Pharm Study: Targretin Causes Tumor Regression SAN DIEGO -- Ligand Pharmaceuticals Inc. (LGND) published results of a third preclinical study which showed its Targretin drug caused complete or partial regression in 94% of animals with tamoxifen-resistant primary breast tumors when added to tamoxifen therapy. In a press release Wednesday, the company said the study "clearly demonstrates Targretin can overcome a tamoxifen failure in this pre-clinical study and may provide a rationale for combining Targretin with tamoxifen after mammary tumors have failed initial tamoxifen therapy................